Jiangsu Hengrui Pharmaceuticals Co.,Ltd. (600276.SH) has announced that it and its subsidiaries recently received Drug Clinical Trial Approval Notices from the National Medical Products Administration for ten drug candidates, paving the way for upcoming clinical studies.

The approved candidates include HRS-7172 tablets, adebrelimab injection, SHR-4610 injection, SHR-8068 injection, SHR-9839 for injection (sc), SHR-1826 for injection, bevacizumab injection, HRS-4642 injection, HRS-6093 tablets, and HRS-7058 capsules.

Per the Drug Administration Law of the People's Republic of China and relevant regulations, after review, the clinical trial applications for the aforementioned drug candidates, which were accepted on May 18, 2026, meet the requirements for drug registration and have been approved for clinical trials.

The specific study outlined is an open-label, multicenter Phase Ib/II clinical study evaluating the safety, tolerability, and efficacy of HRS-7172 in combination with antitumor therapy in participants with solid tumors.